<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04210115</url>
  </required_header>
  <id_info>
    <org_study_id>3475-975</org_study_id>
    <secondary_id>2019-002006-51</secondary_id>
    <secondary_id>MK-3475-975</secondary_id>
    <secondary_id>KEYNOTE-975</secondary_id>
    <secondary_id>PHRR200210-002490</secondary_id>
    <secondary_id>205261</secondary_id>
    <nct_id>NCT04210115</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of treatment with definitive&#xD;
      chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo&#xD;
      with respect to Overall Survival (OS) and Event-free Survival (EFS) in:&#xD;
&#xD;
        -  participants with esophageal squamous cell carcinoma (ESCC),&#xD;
&#xD;
        -  participants whose tumors express Programmed Death-Ligand 1 (PD-L1) Combined Positive&#xD;
           Score (CPS) ≥10, and&#xD;
&#xD;
        -  all participants.&#xD;
&#xD;
      The primary study hypotheses are that dCRT+ pembrolizumab is better than dCRT + placebo with&#xD;
      respect to:&#xD;
&#xD;
        -  OS in participants with ESCC,&#xD;
&#xD;
        -  OS in participants whose tumors express PD-L1 CPS ≥10,&#xD;
&#xD;
        -  OS in all participants,&#xD;
&#xD;
        -  EFS in participants with ESCC,&#xD;
&#xD;
        -  EFS in participants whose tumors express PD-L1 CPS ≥10, and&#xD;
&#xD;
        -  EFS in all participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants receive pembrolizumab or placebo PLUS one of two chemotherapy regimens PLUS&#xD;
      radiation therapy for up to approximately one year. The chemotherapy regimens are either:&#xD;
&#xD;
        -  FP (5-fluorouracil [5-FU] + cisplatin) or&#xD;
&#xD;
        -  FOLFOX (5-FU + oxaliplatin + leucovorin or levoleucovorin).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">February 21, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 21, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to ~72 months</time_frame>
    <description>OS is defined as the time from randomization to death from any cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free Survival (EFS)</measure>
    <time_frame>Up to ~60 months</time_frame>
    <description>EFS is defined as the time from randomization to an event defined as local, regional, or distant recurrence as assessed by blinded independent central review (BICR) based on imaging or biopsy if indicated (if biopsy is accompanied with radiological recurrence of primary disease as evaluated by investigator); or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with an adverse event (AE)</measure>
    <time_frame>Up to ~15 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants discontinuing study treatment due to an adverse event (AE)</measure>
    <time_frame>Up to ~12 months</time_frame>
    <description>An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma (ESCC)</condition>
  <condition>Gastroesophageal Junction Carcinoma (GEJC)</condition>
  <condition>Esophageal Adenocarcinoma (EAC)</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive pembrolizumab 200 mg on Day 1 of each 3-week cycle for 8 cycles followed by pembrolizumab 400 mg on Day 1 of each 6-week cycle for 5 cycles PLUS either:&#xD;
FP therapy: cisplatin 75 mg/m^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-fluorouracil (5-FU)] 1000 mg/m^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gray [Gy] in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR&#xD;
FOLFOX therapy: oxaliplatin 85 mg/m^2 AND either leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.&#xD;
All treatments except radiotherapy are given by intravenous (IV) infusion. Total treatment duration is approximately 1 year.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo on Day 1 of each 3-week cycle for 8 cycles followed by placebo on Day 1 of each 6-week cycle for 5 cycles PLUS either:&#xD;
FP therapy: cisplatin 75 mg/m^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-FU 1000 mg/m^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gy in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR&#xD;
FOLFOX therapy: oxaliplatin 85 mg/m^2 AND either leucovorin 400 mg/m^2 OR levoleucovorin 200 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.&#xD;
All treatments except radiotherapy are given by IV infusion. Total treatment duration is approximately 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <other_name>Normal saline solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <other_name>PLATINOL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <other_name>ADRUCIL®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>external radiation</description>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <other_name>calcium folinate</other_name>
    <other_name>folinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levoleucovorin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <other_name>FUSILEV®</other_name>
    <other_name>calcium levofolinate</other_name>
    <other_name>levofolinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <arm_group_label>Placebo+FP or FOLFOX Therapy+Radiotherapy</arm_group_label>
    <other_name>ELOXATIN®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has histologically or cytologically confirmed diagnosis of CTX N+ M0 or cT2-T4a NX M0&#xD;
             ESCC, GEJC, EAC, or histologically or cytologically confirmed diagnosis of cTX N+ M1&#xD;
             cervical or upper thoracic esophageal carcinoma with supraclavicular lymph node&#xD;
             metastases only&#xD;
&#xD;
          -  Is deemed suitable for dCRT&#xD;
&#xD;
          -  Is ineligible for curative surgery based on the documented opinion of a qualified&#xD;
             medical/surgical/radiation oncologist&#xD;
&#xD;
          -  Is not expected to require tumor resection during the course of the study&#xD;
&#xD;
          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 3&#xD;
             days of the first dose of study treatment.&#xD;
&#xD;
          -  Has adequate organ function&#xD;
&#xD;
          -  Male participants must use adequate contraception (a male condom plus partner use of&#xD;
             an additional contraceptive method) unless confirmed to be azoospermic (vasectomized&#xD;
             or secondary to medical cause) and refrain from donating sperm during the study&#xD;
             treatment period and through 90 days after the last dose of chemotherapy&#xD;
&#xD;
          -  Female participants who are a Woman of Childbearing Potential (WOCBP) must use&#xD;
             contraception that is highly effective (with a failure rate of &lt;1% per year), with low&#xD;
             user dependency, or be abstinent from heterosexual intercourse as their preferred and&#xD;
             usual lifestyle, during the study treatment period through 180 days after the last&#xD;
             dose of chemotherapy or 120 days after the last dose of pembrolizumab, whichever is&#xD;
             greater, and agree not to donate eggs to others or freeze/store for her own use for&#xD;
             the purpose of reproduction during this period&#xD;
&#xD;
          -  Female participants must not be pregnant or breastfeeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has direct invasion of tumor into adjacent organs such as the aorta or trachea or has&#xD;
             radiographic evidence of &gt;90 degree encasement or invasion of a major blood vessel, or&#xD;
             of intratumoral cavitation&#xD;
&#xD;
          -  Has had major surgery other than for insertion of a feeding tube, open biopsy, or&#xD;
             significant traumatic injury within 28 days prior to randomization, or anticipates the&#xD;
             need for major surgery during study treatment; participants with gastric or esophageal&#xD;
             fistulae are excluded&#xD;
&#xD;
          -  Has had weight loss of &gt;20% in the previous 3 months&#xD;
&#xD;
          -  Has had prior chemotherapy or radiotherapy for esophageal cancer&#xD;
&#xD;
          -  Has had a myocardial infarction within the past 6 months&#xD;
&#xD;
          -  Has symptomatic congestive heart failure&#xD;
&#xD;
          -  Has received prior therapy with an anti-programmed cell death-1 (anti PD-1),&#xD;
             anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-programmed cell death-ligand&#xD;
             2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory&#xD;
             T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40,&#xD;
             CD137)&#xD;
&#xD;
          -  Has received a live or live-attenuated vaccine within 30 days prior to the first dose&#xD;
             of study intervention; administration of killed vaccines is allowed&#xD;
&#xD;
          -  Has received any prior systemic anticancer therapy for esophageal cancer including&#xD;
             investigational agents&#xD;
&#xD;
          -  Has not recovered from all adverse events (AEs) due to previous non-anticancer&#xD;
             therapies to ≤Grade 1 or Baseline&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             or any other form of immunosuppressive therapy within 7 days prior the first dose of&#xD;
             study treatment&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or has required active treatment&#xD;
             within the past 3 years. Note: Participants with basal cell carcinoma of the skin,&#xD;
             squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma,&#xD;
             cervical cancer in situ) that have undergone potentially curative therapy are not&#xD;
             excluded from the study. Participants with localized prostate cancer that has&#xD;
             undergone potentially curative treatment can be enrolled in the study.&#xD;
&#xD;
          -  Has severe hypersensitivity (≥Grade 3) to pembrolizumab, any of the study chemotherapy&#xD;
             agents, or their excipients&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in past 2 years&#xD;
&#xD;
          -  Has a history of (non-infectious) pneumonitis that required steroids or has current&#xD;
             pneumonitis&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy&#xD;
&#xD;
          -  Has a known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Has a known history of Hepatitis B or known active Hepatitis C virus infection&#xD;
&#xD;
          -  Has a known history of active tuberculosis (TB; Bacillus tuberculosis)&#xD;
&#xD;
          -  Is pregnant or breastfeeding or expecting to conceive or father children within the&#xD;
             projected duration of the study, starting with the screening visit through 120 days&#xD;
             after the last dose of study treatment (180 days for participants receiving cisplatin&#xD;
             who are breastfeeding)&#xD;
&#xD;
          -  Has had an allogenic tissue/solid organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MemorialCare Health System - Long Beach Medical Center-Oncology ( Site 0691)</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>562-933-7866</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute ( Site 0047)</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>706-660-6449</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center ( Site 0023)</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>913-588-2012</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas ( Site 0058)</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>316-613-4313</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center ( Site 0035)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>504-702-3574</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center ( Site 0031)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>443-849-3122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Center ( Site 0034)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-632-5960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Cancer Center ( Site 0685)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-0482</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Missouri ( Site 0688)</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>573-882-4141</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College ( Site 0053)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-962-6200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center ( Site 0044)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>405-271-8001</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Center for Health &amp; Healing 2- CHH2 ( Site 0060)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>503-494-1080</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allegheny Health Network ( Site 0042)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>412-578-1035</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest - Spokane Valley ( Site 0036)</name>
      <address>
        <city>Spokane Valley</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-228-1689</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics ( Site 0033)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>608-265-2789</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Favaloro ( Site 0061)</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <state>Caba</state>
        <zip>C1093AAS</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5411437812001701</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0066)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1264AAA</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+541143043202</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Medico Alexander Fleming ( Site 0063)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+54 11 3221 8900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEMIC ( Site 0064)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1431FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+541152990100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCL Saint Luc ( Site 0162)</name>
      <address>
        <city>Brussels</city>
        <state>Bruxelles-Capitale, Region De</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>003227641274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent ( Site 0163)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3293329500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven ( Site 0161)</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3216344218</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Delta ( Site 0165)</name>
      <address>
        <city>Roeselare</city>
        <state>West-Vlaanderen</state>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3251237215</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Caridade de Ijui ( Site 0088)</name>
      <address>
        <city>Ijui</city>
        <state>Rio Grande Do Sul</state>
        <zip>98700 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+555533319393</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao ( Site 0087)</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5551993590437</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica de Oncologia Reichow ( Site 0085)</name>
      <address>
        <city>Blumenau</city>
        <state>Santa Catarina</state>
        <zip>89010-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+554733805858</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0081)</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>551138932686</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute ( Site 0010)</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>780-5778072</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital - Cancer Care ( Site 0008)</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>6137377700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre ( Site 0011)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>4169466508</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0005)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5148908000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Investigación del Cáncer James Lind ( Site 0106)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4780000</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56994443272</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0103)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4810218</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>56957983173</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Concepcion ( Site 0105)</name>
      <address>
        <city>Concepcion</city>
        <state>Biobio</state>
        <zip>4070038</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56992567286</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Cancer Nuestra Senora de la Esperanza ( Site 0104)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>8330024</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+56991612199</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>900 Hospital of the Joint ( Site 0509)</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613774562945</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University ( Site 0538)</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>86 13806000926</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital ( Site 0514)</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>13907174495</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital ( Site 0515)</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613973135460</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huai an First People s Hospital ( Site 0526)</name>
      <address>
        <city>Huai An</city>
        <state>Jiangsu</state>
        <zip>223001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86051784992012</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital ( Site 0519)</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613601458518</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University ( Site 0522)</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>15895236960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University ( Site 0524)</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <zip>212000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8651185023852</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Cancer Hospital ( Site 0512)</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0791-88313632</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital ( Site 0503)</name>
      <address>
        <city>Shangai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>021-22200000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital ( Site 0501)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>021-22200000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University ( Site 0502)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86 13817076800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital ( Site 0527)</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8618908178818</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital ( Site 0505)</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+02223340123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hangzhou First People's Hospital ( Site 0530)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613505710131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital ( Site 0523)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310018</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8657186090073</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital ( Site 0529)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>13777461935</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet ( Site 0199)</name>
      <address>
        <city>Copenhagen</city>
        <state>Hovedstaden</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4535450818</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital ( Site 0200)</name>
      <address>
        <city>Odense</city>
        <state>Syddanmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4540467104</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SA Pohja-Eesti Regionaalhaigla ( Site 0201)</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3726171245</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SA Tartu Ulikooli Kliinikum ( Site 0202)</name>
      <address>
        <city>Tartu</city>
        <state>Tartumaa</state>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3727318815</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse ( Site 0236)</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+550231455419</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc ( Site 0223)</name>
      <address>
        <city>Dijon</city>
        <state>Cote-d Or</state>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33345348051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Limoges Hopital Dupuytren ( Site 0225)</name>
      <address>
        <city>Limoges</city>
        <state>Haute-Vienne</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33555056267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Centre Rene Huguenin ( Site 0237)</name>
      <address>
        <city>Saint-Cloud</city>
        <state>Ile-de-France</state>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33 1 47 11 15 15</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hotel Dieu Nantes ( Site 0230)</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33244768398</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut De Cancerologie De Lorraine ( Site 0222)</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33383598332</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine ( Site 0228)</name>
      <address>
        <city>Avignon</city>
        <state>Provence-Alpes-Cote-d Azur</state>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33490276268</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD Vendee ( Site 0227)</name>
      <address>
        <city>La Roche sur Yon</city>
        <state>Vendee</state>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+0033251446161</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marienhospital Stuttgart Vincenz von Paul Kliniken gGmbH ( Site 0253)</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wurttemberg</state>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4971164898107</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln ( Site 0251)</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4922147887009</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Muenster ( Site 0248)</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+492518352712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Campus Virchow Klinikum ( Site 0250)</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00493045050</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Facharztzentrum Eppendorf ( Site 0242)</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00494036035220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0122)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50222783107</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastrosoluciones ( Site 0126)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50222695000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncomedica ( Site 0125)</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50256973689</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Grupo Medico Angeles ( Site 0121)</name>
      <address>
        <city>Guatemala</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50240492110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medi-K Cayala ( Site 0124)</name>
      <address>
        <city>Guatemala</city>
        <zip>01016</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50255505555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Medico Integral De Cancerología (CEMIC) ( Site 0123)</name>
      <address>
        <city>Quetzaltenango</city>
        <zip>09002</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+50259458053</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pamela Youde Nethersole Eastern Hospital ( Site 0543)</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+85225954183</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital. ( Site 0542)</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+85229902393</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital ( Site 0541)</name>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>22554216</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem AOK ( Site 0265)</name>
      <address>
        <city>Pecs</city>
        <state>Baranya</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3672536000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 0262)</name>
      <address>
        <city>Gyula</city>
        <state>Bekes</state>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+36704533531</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orszagos Onkologiai Intezet ( Site 0263)</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3612248600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont ( Site 0261)</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3652255840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Oncologico Veneto ( Site 0298)</name>
      <address>
        <city>Padova</city>
        <state>Abruzzo</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390498215910</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato ( Site 0295)</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Milano</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3902527741</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana - Presidio Santa Chiara ( Site 0294)</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+39050993841</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII ( Site 0296)</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390352673694</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale di Cremona ( Site 0299)</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390372405242</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0292)</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390223902882</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A. Gemelli ( Site 0297)</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390696734844</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital ( Site 0563)</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81527626111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East ( Site 0562)</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81471331111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center ( Site 0565)</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81455202222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center ( Site 0564)</name>
      <address>
        <city>Kitaadachi-gun</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81487221111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center Hospital and Research Institute ( Site 0566)</name>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81559895222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital ( Site 0561)</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+81335422511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital ( Site 0625)</name>
      <address>
        <city>Hwasun Gun</city>
        <state>Jeonranamdo</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8218990000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center ( Site 0626)</name>
      <address>
        <city>Goyang-si</city>
        <state>Kyonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center ( Site 0623)</name>
      <address>
        <city>Songpagu</city>
        <state>Seoul</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8216887575</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System ( Site 0624)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82 2 2228 1004</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center ( Site 0622)</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82215993114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital ( Site 0621)</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8215779966</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Neoplasicas ( Site 0141)</name>
      <address>
        <city>Lima</city>
        <zip>15038</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51992783190</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Arzobispo Loayza ( Site 0143)</name>
      <address>
        <city>Lima</city>
        <zip>15082</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51987421693</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica San Gabriel ( Site 0142)</name>
      <address>
        <city>Lima</city>
        <zip>15088</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+51 998718091</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baguio General Hospital and Medical Center ( Site 0603)</name>
      <address>
        <city>Baguio City</city>
        <state>Benguet</state>
        <zip>2600</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+639985529020</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cebu Doctors University Hospital ( Site 0604)</name>
      <address>
        <city>Cebu City</city>
        <state>Cebu</state>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+63322386248</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Medical City-Iloilo ( Site 0602)</name>
      <address>
        <city>Iloilo City</city>
        <state>Iloilo</state>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+639228372408</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke s Medical Center ( Site 0601)</name>
      <address>
        <city>Quezon</city>
        <state>National Capital Region</state>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+639175431178</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHLN Hospital Santa Maria ( Site 0376)</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351217805000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 0371)</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351225084000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0392)</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40264598361</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C. Radiotherapy Center Cluj S.R.L ( Site 0391)</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>407280</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40742206212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0394)</name>
      <address>
        <city>Craiova</city>
        <state>Dolj</state>
        <zip>200347</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40727774974</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Topmed ( Site 0398)</name>
      <address>
        <city>Targu-Mures</city>
        <state>Mures</state>
        <zip>540156</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40740277907</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C.Focus Lab Plus S.R.L ( Site 0395)</name>
      <address>
        <city>Bucuresti</city>
        <zip>022548</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40721298677</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean De Urgenta Constanta ( Site 0393)</name>
      <address>
        <city>Constanta</city>
        <zip>900591</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40241503485</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>GBUZ Republican Clinical Oncological Dispensary-Antitumor drug therapy department ( Site 0430)</name>
      <address>
        <city>Ufa</city>
        <state>Baskortostan, Respublika</state>
        <zip>450054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79050022295</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaluga Regional Clinical Oncology Center ( Site 0424)</name>
      <address>
        <city>Kaluga</city>
        <state>Kaluzskaja Oblast</state>
        <zip>248007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+7 4842 72 57 61</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Main Military Clinical Hospital n.a. N.N.Burdenko ( Site 0421)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+7(499) 263-05-39</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 0429)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+7 (499) 190-40-27</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SBHI Samara Regional Clinical Oncology Dispensary ( Site 0420)</name>
      <address>
        <city>Samara</city>
        <state>Samarskaya Oblast</state>
        <zip>443031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79272143459</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pavlov First Saint Petersburg State Medical University ( Site 0426)</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical institute named after Berezin Sergey ( Site 0417)</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78122440024</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Oncology Hospital ( Site 0411)</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovskaya Oblast</state>
        <zip>620036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+73433561505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 0412)</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan, Respublika</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78435257346</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Med Foundation. Kaohsiung Branch ( Site 0643)</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88677317123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital ( Site 0646)</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886422052121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital-Radiation Oncology ( Site 0647)</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886423592525</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital ( Site 0645)</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88662353535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 0641)</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886223123456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Koo Foundation Sun Yat-Sen Cancer Center ( Site 0644)</name>
      <address>
        <city>Taipei</city>
        <zip>11259</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886228970011</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation. Linkou ( Site 0642)</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+88633281200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>İstanbul University Cerrahpaşa Medical Faculty ( Site 0452)</name>
      <address>
        <city>Istambul</city>
        <state>Istanbul</state>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905324167355</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Ankara Hastanesi ( Site 0461)</name>
      <address>
        <city>Ankara</city>
        <zip>06520</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905067521275</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 0451)</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902166065200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi ( Site 0457)</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905325566065</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Izmir Katip Celebi Universitesi Ataturk Egitim ve Arastirma Hastanesi ( Site 0458)</name>
      <address>
        <city>Izmir</city>
        <zip>35360</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905324078648</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary ( Site 0474)</name>
      <address>
        <city>Aberdeen</city>
        <state>Aberdeen City</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>441224550061</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Trust ( Site 0477)</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+441223216083</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College Hospital NHS Foundation Trust ( Site 0701)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0203 447 9093</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 0283)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442086426011</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital-Medical Oncology ( Site 0471)</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+44 20 3312 6666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust ( Site 0476)</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>441159691169</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital (Sutton) ( Site 0281)</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4473528171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust ( Site 0282)</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4401614463209</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital ( Site 0478)</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+447469141803</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Programmed Cell Death-1 (PD1, PD-1)</keyword>
  <keyword>Programmed Death-Ligand 1 (PDL1, PD-L1)</keyword>
  <keyword>Programmed Death-Ligand 2 (PDL2, PD-L2)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

